Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir DDI with Cyclosporine and Tacrolimus in Healthy Subjects
NCT02016625Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of faldaprevir in hepatitis C (HCV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Cyclosporine in Plasma Over the Time Interval From 0 Extrapolated to Infinity up to 168 hours, Area Under the Concentration-time Curve of Cyclosporine in Plasma Over the Time Interval From 0 to the Last Quantifiable Point up to 168 hours and 7 more. Started Dec 2013; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02016625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016625.